27/04/2019
SUMMARY AND RECOMMENDATIONS FOR MANAGEMENT OF GONORRHEA
● Gonococcal infections, including urethritis, cervicitis, epididymitis, and proctitis, are a significant cause of morbidity among s*xually active men and women.
● Since treatment failure for gonococcal eradication has significant public health implications, it is desirable for therapeutic regimens to have efficacy rates of greater than 95 percent. The selection of the treatment regimen must also include consideration of drug resistance and potential copathogens, such as Chlamydia trachomatis and Mycoplasma ge***alium.
● High microbiologic cure rates of gonococcal infection had been documented for multiple classes of drugs in the past. However, surveillance of resistance patterns in N. gonorrhoeae worldwide have demonstrated increasing resistance to multiple classes of antibiotics including penicillins, tetracyclines, macrolides, and fluoroquinolones. Of the cephalosporin class of drugs, ceftriaxone has the lowest rates of gonococcal drug resistance in epidemiologic surveys.
● A low but increasing proportion of isolates with decreased susceptibility to ceftriaxone are being reported worldwide. Because of this trend and the lack of new, effective antimicrobials in advanced product development, we suggest dual rather than monotherapy for the treatment of gonococcal infections (Grade 2C).
● For the treatment of suspected or confirmed uncomplicated uroge***al gonococcal infection, we recommend ceftriaxone as the first agent (Grade 1B). For the second agent, we suggest azithromycin (Grade 2C). Ceftriaxone is administered as a single injection of a 250 mg dose at the point of care. Azithromycin is given orally as a single dose (1 g) and also has activity against chlamydia, which is a common copathogen.
● Pharyngeal infections may be somewhat more difficult to cure and may serve as an important reservoir of asymptomatic and resistant infections.
● Pregnant women with uncomplicated gonorrheal infection should be treated with dual therapy with ceftriaxone plus azithromycin since doxycycline should be avoided during pregnancy. In addition to retesting three months following therapy, pregnant women at continued high risk for gonococcal infection should be retested during the third trimester.
● The management of the penicillin allergic patient depends upon the clinical suspicion of true allergy and the type of the allergy (eg, morbilliform rash versus IgE-mediated reactions, such as urticaria).
● Persons diagnosed with a s*xually transmitted infection are at high risk for HIV infection and should be offered testing.
● Patients who finish a recommended regimen for treatment of uncomplicated gonorrheal infections do not need to return for a test of cure. A test of cure is performed with culture (at seven days following therapy) or nucleic acid amplification tests (NAATs; at 14 days following therapy) for any patient who receives an alternate regimen (eg, a cefixime-based regimen) for oropharyngeal gonococcal infection. Patients who continue to be symptomatic should be reevaluated for treatment failure or other s*xually transmitted infections. All patients with documented gonococcal infection should be retested three months following treatment to evaluate for reinfection.
● Treatment failure is suspected in individuals with persistent or recurrent symptoms soon (eg, three to five days) after completing therapy for a documented gonococcal infection. If reinfection is unlikely, relevant specimens (eg, urethral, oropharyngeal, and/or re**al samples depending on exposure) should be submitted for culture and NAAT for N. gonorrhoeae and isolates sent for susceptibility testing. These cases should also be reported to governmental public health agencies.
● Treatment of s*xual partners is essential for preventing reinfection and controlling the spread of N. gonorrhoeae. For s*x partners of patients with documented gonococcal infection, we suggest not routinely employing expedited partner therapy (Grade 2C). Instead, we prefer evaluation and management through traditional strategies of public health or patient notification. However, if a heteros*xual partner cannot be evaluated and managed in this manner, delivery of oral cefixime and azithromycin through expedited partner therapy is a reasonable approach.
REFERENCES
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. S*xually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606.
Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 Suppl 3:S84.
Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl 1:S47.
Weston EJ, Workowski K, Torrone E, et al. Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea - STD Surveillance Network, United States, 2016. MMWR Morb Mortal Wkly Rep 2018; 67:473.
Fifer H, Natarajan U, Jones L, et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med 2016; 374:2504.
Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.
Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis ge***al infection: how much do we know? J Infect Dis 2010; 201 Suppl 2:S156.
Manhart LE, Broad JM, Golden MR. Mycoplasma ge***alium: should we treat and how? Clin Infect Dis 2011; 53 Suppl 3:S129.
Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? S*x Transm Infect 2012; 88:6.
European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2013. Stockholm: ECDC; 2015.
Australian Gonococcal Surveillance Programme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on November 01, 2014).
World Health Organization. The Gonococcal Antimicrobial Surveillance Programme (GASP) http://www.who.int/reproductivehealth/topics/rtis/gonococcal_resistance/en/ (Accessed on July 10, 2017).
Centers for Disease Control and Prevention (CDC). Update to CDC's s*xually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.
Sparling PF. Antibiotic resistance in Neisseria gonorrhoeae. Med Clin North Am 1972; 56:1133.
Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401.
Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have s*x with men and men who have s*x exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.
Unemo M, Bradshaw CS, Hocking JS, et al. S*xually transmitted infections: challenges ahead. Lancet Infect Dis 2017; 17:e235.
Brittain C, Childs M, Duley L, et al. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. Trials 2016; 17:558.
Quaye N, Cole MJ, Ison CA. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. J Antimicrob Chemother 2014; 69:1568.
Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018; 23.
Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990; 264:1413.
Centers for Disease Control and Prevention. S*xually Transmitted Disease Surveillance 2015: Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles. Atlanta: U.S. Department of Health and Human Services; 2017.https://www.cdc.gov/std/stats15/gisp2015/GISP-Supplement-AggrFigs_AggrTables_Clinic-Profiles_2015.pdf (Accessed on July 10, 2017).
Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med 2017; 14:e1002344.
Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001; 45:3603.
Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275.
Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10:555.
Singh AE, Gratrix J, Martin I, et al. Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian S*xually Transmitted Infection Clinics, 2010-2013. S*x Transm Dis 2015; 42:331.
Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163.
Centers for Disease Control and Prevention (CDC). Update to CDC's S*xually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590.
https://youtu.be/iFwlnljV2Go
This animation details the history of drug-resistant gonorrhea in the United States, the dangers of untreatable gonorrhea, and why this issue must remain a t...